On October 26, 2021, the 2021 Cell Industry Conference / 2021 7th (Shenzhen) Cell and Tumor Precision Medicine Summit Forum and 2021 Gene and Precision Diagnostics & Therapeutics (Shenzhen) Summit Forum opened in Shenzhen. Dr. Hu Junyuan, Chairman of Beike Biotech and President of the Shenzhen Life Sciences Industry Association, was invited to attend the summit and deliver a thematic report.
The Cell Industry Conference has been successfully held for six editions. Through ongoing exploration, development, accumulation, and refinement, it has grown into a major event in China's cell industry. This summit focused on topics including policy and regulatory standards, regulation, processes and industrialization progress, cell and gene therapy, 3D cell culture and organoids, oncolytic viruses, treatment and drug development for solid tumors, and clinical research and treatment progress. Authoritative experts and industry pioneers from national drug review and regulatory agencies, scientific research institutes, medical institutions, innovative drug companies, biotherapy, biotechnology and service enterprises, upstream and downstream enterprises along the industry chain, industrial parks, investment institutions, and industry associations were invited to share insights, exchange ideas, and showcase products.
Beike Biotech's Chairman was invited to deliver a keynote speech via voice link. Dr. Hu Junyuan said that in the face of the wave of intelligence and digitalization, Beike Biotech has consistently advocated a path of intelligent transformation in cell R&D innovation and standardized production. Driven by both AI and innovative R&D, Beike Biotech is steadily advancing toward intelligent operations across cell-industry manufacturing, technology R&D, and clinical translation. Dr. Liao Yan, Manager of Beike Biotech's R&D Center, also delivered an outstanding presentation at the summit on the theme "Development of the Stem Cell Therapy Industry — Foundations and the Outlook for Translational Application".
